You are here: Industry Insights > Fresenius Kabi

News List

Fresenius Kabi invests in Pre-Filled Syringe Capacities for US and EU supply 20 Sep 2021 cphi-online
September 23, 2021
As a safe, effective and convenient way to administer injectable medications, pre-filled syringes (PFS) have become the injection system of choice for a growing number of drugs.
Fresenius Kabi Recalls Ketorolac Tromethamine Injection americanpharmaceuticalreview
January 15, 2021
Fresenius Kabi USA is voluntarily recalling a single lot of Ketorolac Tromethamine Injection, USP, 30 mg/mL, 1 mL fill in a 2 mL amber vial to the user level due to the presence of particulate matter.
Fresenius Kabi Introduces RFID Smart Labels for Essential Meds contractpharma
August 24, 2020
Prefilled syringes and vials will be the first presentations featured as part of the new +RFID portfolio.
Fresenius Kabi Recalls Two Lots of Dexmedetomidine Hydrochloride Injection americanpharmaceuticalreview
July 28, 2020
Fresenius Kabi USA is voluntarily recalling two lots of Dexmedetomidine HCl in 0.9% Sodium Chloride Injection, 200 mcg/50 mL (4 mcg / mL), 50 mL fill in a 50 mL vial.
Fresenius Kabi Expands MicroVault Packaging contractpharma
June 24, 2020
Simplist MicroVault packaging supports diversion deterrence and secure dispensing of controlled substances.
Fresenius Kabi recalls 13 lots of ketorolac tromethamine injection europeanpharmaceuticalreview
April 24, 2020
The FDA has announced that Fresenius Kabi is voluntarily recalling 13 lots of ketorolac tromethamine injection due to particulate matter found in reserve sample vials.
Fresenius Kabi Issues Recall of 13 Lots of Ketorolac Tromethamine Injection americanpharmaceuticalreview
April 21, 2020
Fresenius Kabi is voluntarily recalling 13 lots of Ketorolac Tromethamine Injection, USP, 30 mg/mL, 1 mL fill in a 2 mL amber vial and ...
Vizient and Fresenius Kabi Expand Partnership contractpharma
December 04, 2019
Vizient has signed an agreement with Fresenius Kabi to supply six critical care drugs under Vizient’s successful Novaplus private label pharmacy program.
Fresenius Kabi Issues Recall of Two Lots of Fluorouracil Injection americanpharmaceuticalreview
July 04, 2019
Fresenius Kabi is voluntarily recalling two lots of Fluorouracil Injection, USP 5g/100mL (50mg/mL), 100mL fill in 100mL vials, to the user level due to the potential for glass particulate.
Fresenius Kabi terminates $4.3-billion merger agreement with Akorn firstwordpharma
April 23, 2018
Fresenius Kabi announced Sunday that it has decided to abandon its planned takeover of Akorn, citing the latter's "failure to fulfill several closing conditions."